Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015)
Dechuang Jiao, Jiujun Zhu, Xianfu Sun, Zhenduo Lu, Jianghua Qiao, Xiuchun Chen, Chengzheng Wang, Min Yan, Chongjian Zhang, Lianfang Li, Jianfei Wang, Min Jin, Yijia Wu, Zhenzhen Liu · 2026
Read Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015) by Dechuang Jiao, Jiujun Zhu, Xianfu Sun, Zhenduo Lu, Jianghua Qiao, Xiuchun Chen, Chengzheng Wang, Min Yan, Chongjian Zhang, Lianfang Li, Jianfei Wang, Min Jin, Yijia Wu, Zhenzhen Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13623843.txt.
Description
Dechuang Jiao and thirteen co-authors published a phase two trial in twenty twenty-six on a targeted drug given before surgery for a common breast cancer type. SHR-A1811 is an antibody-drug conjugate aimed at HER2, tested here in hormone-sensitive tumors with low HER2 levels. Sixty-six women with untreated, sizable tumors enrolled.
Patients received eight cycles of the drug every three weeks before surgery. The response rate reached about eighty-two percent, comfortably above the trial's preset bar. Pathological complete response and survival endpoints were also tracked. Safety data accompanied the efficacy analysis. The single-arm design lacks a comparison group, but the shrinkage numbers support moving this pre-surgery strategy into larger randomized trials.
Catalog record
| CREATOR | Dechuang Jiao, Jiujun Zhu, Xianfu Sun, Zhenduo Lu, Jianghua Qiao, Xiuchun Chen, Chengzheng Wang, Min Yan, Chongjian Zhang, Lianfang Li, Jianfei Wang, Min Jin, Yijia Wu, Zhenzhen Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |